相关实验视频

Updated: Jun 25, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

D-carvone对非小细胞肺癌 (NSCLC) 的多重向作用:基于网络药理学的研究

Rasha Irshad¹, Faiqah Batool¹, Nafis Raj²

¹Virology and Oncology Lab, Department of Biotechnology, Jamia Millia Islamia, New Delhi, India.

Toxicology and applied pharmacology

|May 25, 2024

概括

D-carvone (CN) 显示出作为一种新型非小细胞肺癌 (NSCLC) 治疗的潜力. 这项研究确定了关键目标,并证明了CN.

科学领域:

瘤学和药理学方面的研究.
自然产品化学自然产品化学
计算生物学计算生物学

背景情况:

非小细胞肺癌 (NSCLC) 是一种异质的恶性瘤,现有的向和免疫疗法需要新的辅助药物.
天然产品具有有前途的化学预防潜力,毒性最小,需要对D-carvone (CN) 等药物进行研究,用于NSCLC治疗.
对D-carvone (CN) 对NSCLC的治疗疗效在很大程度上仍未被探索.

研究的目的:

通过网络药理学和分子对接,阐明D-carvone (CN) 对非小细胞肺癌 (NSCLC) 的作用机制.
在NSCLC中识别D-carvone (CN) 调节的核心标和生物途径.
在体外验证D-carvone (CN) 的抗癌作用.

主要方法:

针对NSCLC的D-carvone (CN) 的网络药理学分析,确定了77个假定目标.
使用Cytoscape构建一个"化合物目标疾病"网络,以确定5个核心目标 (JAK2,ERK1,ESR1,GSK3B,HSP90AA1).
在体外验证包括细胞增殖,克隆原性,伤口愈合测定,亡分析 (流细胞测量,西部涂抹) 和分子对接.

主要成果:

网络药理学为D-carvone (CN) 确定了77个潜在的抗NSCLC标,其中5个核心标被突出.
分子对接证实了D-carvone (CN) 和已识别的核心目标之间的强有力的结合相互作用.
实验室研究表明,D-carvone (CN) 显著抑制了NSCLC细胞增殖,克隆原性和伤口愈合,同时促进了亡.

结论:

D-carvone (CN) 对非小细胞肺癌 (NSCLC) 细胞系表现出显著的治疗作用.
该研究描述了D-carvone (CN) 的抗癌机制,支持其作为新药候选药物的潜力.
对D-carvone (CN) 用于NSCLC治疗的进一步调查是有必要的.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.这是一种D-Carvone.JAK2/STAT3 3 的情况.在NSCLCLC中,我们可以看到NSCLCLC.自然产品自然产品网络药理学网络药理学

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...